集成级联纳米酶具有抗衰变活性,用于动脉样硬化治疗
Wanling Liu1, Yihong Zhang1, Gen Wei1
1College of Engineering and Applied Sciences, Nanjing National Laboratory of Microstructures, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, 210023, Nanjing, Jiangsu, China.
Angewandte Chemie (International ed. in English)
|June 20, 2023
概括
这项研究引入了一种新的纳米酶,通过向衰老细胞和减少氧化应激来对抗动脉样硬化. 这种双重作用的方法有效地抑制了小鼠的疾病进展,提供了一个有前途的新治疗策略.
科学领域:
- 生物医学工程 生物医学工程
- 心血管研究研究心血管研究
- 纳米技术纳米技术
背景情况:
- 衰老细胞是动脉样硬化发展和进展的关键驱动因素.
- 动脉硬性斑块微环境涉及衰老细胞和反应性氧物种 (ROS) 之间的相互作用,加剧了疾病.
- 针对衰老细胞和氧化应激,为动脉样硬化提供了潜在的治疗途径.
研究的目的:
- 开发和评估一种新型的级联纳米酶,其结合抗衰变和抗氧化活性,用于动脉样硬化治疗.
- 研究纳米酶在缓解细胞衰老,炎症和泡细胞形成方面的有效性.
- 在动脉样硬化小鼠模型中评估纳米酶的治疗潜力.
主要方法:
- 开发一种集成级联纳米酶 (MSe1),具有超氧化物脱氧化酶和甲过氧化酶类活性.
- 在体外评估MSe1对人类静脉内皮细胞 (HUVEC) 衰老,ROS排泄和氧化低密度脂蛋白 (oxLDL) 在巨细胞和HUVEC中吸收的影响.
- 在体内评估MSe1在患有动脉样硬化症的阿波利波蛋白E缺陷 (ApoE-/-) 小鼠中的疗效.
主要成果:
- MSe1纳米酶通过保护DNA和减少巨细胞和HUVEC中的细胞内ROS减弱了HUVEC衰老,从而减弱了炎症.
- MSe1通过降低oxLDL内部化来抑制泡细胞的形成.
- 静脉注射MSe1显著抑制了ApoE-/-小鼠的动脉样硬化形成,减少了氧化应激,炎症和老化细胞在斑块中的透.
结论:
- 成功开发了一种具有双重抗衰变和抗氧化特性的新型级联纳米酶 (MSe1).
- MSe1纳米酶通过向关键的病理机制,证明了对动脉样硬化有显著的治疗潜力.
- 结合抗衰老和抗氧化应激策略,为动脉样硬化的有效治疗提供了一个有前途的方法.
更多相关视频
相关概念视频
01:26Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
01:30Atherosclerosis I: Introduction
13
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
13
01:23Atherosclerosis IV: Nursing Management
26
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
26
02:30siRNA - Small Interfering RNAs
16.9K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
16.9K
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
16
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
16